Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
(NASDAQ:SCNI) JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innova...
Did management provide guidance on upcoming milestones, product launches, or regulatory events that could affect the stock's volatility?
What does the strengthened balance sheet mean for cash runway and potential future R&D or acquisition spending?
How does the reported CDMO revenue growth compare to market expectations and previous quarters?
14 days ago